Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study

BACKGROUND: DFN-11, a 3 mg sumatriptan subcutaneous (SC) autoinjector for acute treatment of migraine, has not been assessed previously in multiple attacks. The objective of this study was to evaluate the efficacy, tolerability, and safety of DFN-11 in the acute treatment of multiple migraine attack...

Descripción completa

Detalles Bibliográficos
Autores principales: Landy, Stephen, Munjal, Sagar, Brand-Schieber, Elimor, Rapoport, Alan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093831/
https://www.ncbi.nlm.nih.gov/pubmed/30112725
http://dx.doi.org/10.1186/s10194-018-0882-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093831/
https://www.ncbi.nlm.nih.gov/pubmed/30112725
http://dx.doi.org/10.1186/s10194-018-0882-y

Ejemplares similares